Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Orbotech Ltd. ORBK. This firm, which is in the Electronics-Measuring Instruments industry, saw EPS growth of 20.6% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 18.3%. Furthermore, the long-term growth rate is currently an impressive 18.8%, suggesting pretty good prospects for the long haul.
Orbotech Ltd. Price and Consensus
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 5.3%. Thanks to this rise in earnings estimates, ORBK has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider ORBK. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for ORBK as well.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment